How schizophrenia and depression disrupt reward circuitry

Current Treatment Options in Neurology

Volumn 9, Issue 5, 2007, Pages 357-362

  Holcomb, Henry H ^a   Rowland, Laura M ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; DEXAMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; GLUTAMIC ACID; KETAMINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; RACLOPRIDE;

AMYGDALOID NUCLEUS; ANHEDONIA; ANXIETY; BEHAVIOR DISORDER; BRAIN DEPTH STIMULATION; COMBINATION CHEMOTHERAPY; COMPULSION; CORPUS STRIATUM; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DRUG DEPENDENCE; ELECTROCONVULSIVE THERAPY; HUMAN; INCIDENCE; LOW DRUG DOSE; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; PARKINSON DISEASE; PREVALENCE; PSYCHOSIS; REVIEW; REWARD; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SYMPTOM; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 34548499296     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-007-0021-6     Document Type: Review

References (53)

1. Berridge KC: The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007, 191:391-431.
2. Grace AA, Floresco SB, Goto Y, Lodge DJ: Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends Neurosci 2007, 30:220-227.
3. Price JL: Subcortical projections from the amygdaloid complex. Adv Exp Med Biol 1986, 203:19-33.
4. Price JL: Prefrontal cortical networks related to visceral function and mood. Ann N Y Acad Sci 1999, 877:383-396.
5. Cheer JF, Wassum KM, Heien ML, et al.: Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 2004, 24:4393-4400.
6. Nestler EJ, Carlezon WA Jr: The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006, 59:1151-1159.
7. Gur RC, Erwin RJ, Gur RE, et al.: Facial emotion discrimination: II. Behavioral findings in depression. Psychiatry Res 1992, 42:241-251.
8. Gur RE, Kohler CG, Ragland JD, et al.: Flat affect in schizophrenia: relation to emotion processing and neurocognitive measures. Schizophr Bull 2006, 32:279-287.
9. Laruelle M: Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998, 42:211-221.
10. Abi-Dargham A, Gil R, Krystal J, et al.: Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
11. Meyer JH, McNeely HE, Sagrati S, et al.: Elevated putamen D(2) receptor binding potential in major depression with motor retardation: an [11C]raclopride positron emission tomography study. Am J Psychiatry 2006, 163:1594-1602.
12. Parsey RV, Oquendo MA, Zea-Ponce Y, et al.: Dopamine D(2) receptor availability and amphetamine-induced dopamine release in unipolar depression. Biol Psychiatry 2001, 50:313-322.
13. Mayberg HS, Lozano AM, Voon V, et al.: Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
14. Zarate CA, Jr, Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
15. Berman RM, Cappiello A, Anand A, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
16. Goforth HW, Holsinger T: Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT 2007, 23:23-25.
17. Tye KM, Janak PH: Amygdala neurons differentially encode motivation and reinforcement. J Neurosci 2007, 27:3937-3945.
18. Spezio ML, Huang PY, Castelli F, Adolphs R: Amygdala damage impairs eye contact during conversations with real people. J Neurosci 2007, 27:3994-3997.
19. Das P, Kemp AH, Flynn G, et al.: Functional disconnections in the direct and indirect amygdala pathways for fear processing in schizophrenia. Schizophr Res 2007, 90:284-294.
20. Das P, Kemp AH, Liddell BJ, et al.: Pathways for fear perception: modulation of amygdala activity by thalamocortical systems. Neuroimage 2005, 26:141-148.
21. Tremblay LK, Naranjo CA, Cardenas L, et al.: Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry 2002, 59:409-416.
22. Tremblay LK, Naranjo CA, Graham SJ, et al.: Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005, 62:1228-1236.
23. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, et al.: Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull 2006, 70:312-321.
24. Valentin VV, Dickinson A, O'Doherty JP: Determining the neural substrates of goal-directed learning in the human brain. J Neurosci 2007, 27:4019-4026.
25. Floresco SB, Tse MT: Dopaminergic regulation of inhibitory and excitatory transmission in the basolateral amygdala-prefrontal cortical pathway. J Neurosci 2007, 27:2045-2057.
26. Grace AA, Rosenkranz JA: Regulation of conditioned responses of basolateral amygdala neurons. Physiol Behav 2002, 77:489-493.
27. Siegle GJ, Thompson W, Carter CS, et al.: Increased amygdala and decreased dorsolateral prefrontal BOLD responses in unipolar depression: related and independent features. Biol Psychiatry 2007, 61:198-209.
28. Abi-Dargham A, Rodenhiser J, Printz D, et al.: Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000, 97:8104-8109.
29. Breier A, Su TP, Saunders R, et al.: Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94:2569-2574.
30. Cooper DC: The significance of action potential bursting in the brain reward circuit. Neurochem Int 2002, 41:333-340.
31. Floresco SB, West AR, Ash B, et al.: Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci 2003, 6:968-973.
32. Heien ML, Wightman RM: Phasic dopamine signaling during behavior, reward, and disease states. CNS Neurol Disord Drug Targets 2006, 5:99-108.
33. Holcomb HH, Lahti AC, Medoff DR, et al.: Sequential regional cerebral blood flow brain scans using PET with H2(15)O demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology 2001, 25:165-172.
34. Holcomb HH, Lahti AC, Medoff DR, et al.: Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology 2005, 30:2275-2282.
35. Rowland LM, Bustillo JR, Mullins PG, et al.: Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 2005, 162:394-396.
36. Mayberg HS, Brannan SK, Mahurin RK, et al.: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8:1057-1061.
37. Kegeles LS, Abi-Dargham A, Zea-Ponce Y, et al.: Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry 2000, 48:627-640.
38. Breier A, Adler CM, Weisenfeld N, et al.: Effects of NMDA antagonism on striatal dopamine release in healthy subjects: application of a novel PET approach. Synapse 1998, 29:142-147.
39. Lahti AC, Holcomb HH, Medoff DR, Tamminga CA: Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
40. Lahti AC, Weiler MA, Tamara Michaelidis BA, et al.: Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25:455-467.
41. Theberge J, Al Semaan Y, Williamson PC, et al.: Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003, 160:2231-2233.
42. Yildiz-Yesiloglu A, Ankerst DP: Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 2006, 147:1-25.
43. Rosenberg DR, Macmaster FP, Mirza Y, et al.: Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 2005, 58:700-704.
44. Auer DP, Putz B, Kraft E, et al.: Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000, 47:305-313.
45. Pfleiderer B, Michael N, Erfurth A, et al.: Effective electro-convulsive therapy reverses glutamate/glutamine deficit in the left anterior cingulum of unipolar depressed patients. Psychiatry Res 2003, 122:185-192.
46. Siegle GJ, Steinhauer SR, Thase ME, et al.: Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 2002, 51:693-707.
47. Takahashi H, Koeda M, Oda K, et al.: An fMRI study of differential neural response to affective pictures in schizophrenia. Neuroimage 2004, 22:1247-1254.
48. Gur RE, McGrath C, Chan RM, et al.: An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry 2002, 159:1992-1999.
49. Hollerman JR, Schultz W: Dopamine neurons report an error in the temporal prediction of reward during learning. Nat Neurosci 1998, 1:304-309.
50. Schultz W, Tremblay L, Hollerman JR: Reward prediction in primate basal ganglia and frontal cortex. Neuropharmacology 1998, 37:421-429.
51. McClure SM, Ericson KM, Laibson DI, et al.: Time discounting for primary rewards. J Neurosci 2007, 27:5796-5804.
52. Pessiglione M, Seymour B, Flandin G, et al.: Dopamine-dependent prediction effors underpin reward-seeking behaviour in humans. Nature 2006, 442:1042-1045.
53. Seymour B, O'Doherty JP, Dayan P, et al.: Temporal difference models describe higher-order learning in humans. Nature 2004, 429:664-667.